Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
focafoca99
focafoca99 Jun. 22 at 2:11 PM
$NTHI benefited from Abu Dhabi IND authorization for NEO212, giving the biotech another development path.
0 · Reply
newsfile_corp
newsfile_corp Jun. 22 at 12:45 PM
https://nfne.ws/302323 $NTHI @wstprnews #BBIO #BIIB #BMY #LLY #NTHI #Advertising #Publishing #NASDAQ #Investing
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 22 at 8:58 AM
$NTHI A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE IND approval for NEO212. #NeOnc #NTHI #BrainCancer #Biotech #ClinicalTrials #UAE #AbuDhabi
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 18 at 6:17 AM
$NTHI NeOnc Technologies is proud to announce that we’ve secured UAE IND approval for NEO212 following successful Phase 1 completion, advancing toward global Phase 2 development. • Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol temozolomide conjugate, in the United Arab Emirates • Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose • Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-secures-uae-ind-approval-neo212-following
0 · Reply
focafoca99
focafoca99 Jun. 17 at 2:41 PM
$NTHI got IND approval in Abu Dhabi for its oral brain‑tumor therapy NEO212.
0 · Reply
BioRich
BioRich Jun. 17 at 11:32 AM
$XBI Nice article on some emerging opportunities from a breadth of sectors. Worth a read and look. My favorite is $SABS but haven't really had much exposure to the others. Anyone have a pros/cons on the others? $CUPR $HYFT $NTHI RGNT GELS? Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge https://stocktwits.com/news-articles///null/cZKfn9YbbdUg3
1 · Reply
STACKD0E
STACKD0E Jun. 17 at 2:00 AM
$MCRP $CRE $NTHI
0 · Reply
focafoca99
focafoca99 Jun. 16 at 6:19 PM
$NTHI snags Abu Dhabi IND approval for NEO212, giving the brain-cancer drug an international development path.
0 · Reply
focafoca99
focafoca99 Jun. 16 at 5:21 PM
$NTHI progressed with its first international IND clearance for NEO212 in the UAE, paving the way for Phase 2 development.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 2:03 PM
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-secures-uae-ind-approval-for-neo-212-following-successful-phase-1-completion-advancing-toward-global-phase-2-development/cZKWr01R74c
0 · Reply
Latest News on NTHI
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Jun 22, 2026, 8:45 AM EDT - 1 day ago

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Jun 17, 2026, 9:18 AM EDT - 5 days ago

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

Jun 16, 2026, 1:49 PM EDT - 6 days ago

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

Jun 16, 2026, 9:00 AM EDT - 6 days ago

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

NeOnc Technologies files to sell 555,554 shares of common stock for holders

2026-06-15T20:31:23.000Z - 7 days ago

NeOnc Technologies files to sell 555,554 shares of common stock for holders

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

Jun 15, 2026, 8:35 AM EDT - 8 days ago

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

Jun 9, 2026, 8:45 AM EDT - 14 days ago

The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade

The Next Great AI Revolution May Be Drug Delivery

May 29, 2026, 9:05 AM EDT - 24 days ago

The Next Great AI Revolution May Be Drug Delivery

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

May 19, 2026, 10:28 AM EDT - 4 weeks ago

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

NeOnc Technologies initiated with a Buy at Alliance Global

2026-05-19T11:05:51.000Z - 5 weeks ago

NeOnc Technologies initiated with a Buy at Alliance Global

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

May 18, 2026, 9:00 AM EDT - 5 weeks ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

NeOnc Technologies initiated with a Buy at Maxim

2026-05-18T12:00:00.000Z - 5 weeks ago

NeOnc Technologies initiated with a Buy at Maxim

Biotech's Next Wave May Already be in Motion

May 7, 2026, 8:45 AM EDT - 6 weeks ago

Biotech's Next Wave May Already be in Motion

Where Executives Are Doubling Down on Their Companies' Fortunes

May 6, 2026, 8:35 AM EDT - 6 weeks ago

Where Executives Are Doubling Down on Their Companies' Fortunes

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

May 5, 2026, 9:00 AM EDT - 6 weeks ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc Technologies initiated with a Buy at BTIG

2026-04-24T10:17:12.000Z - 2 months ago

NeOnc Technologies initiated with a Buy at BTIG

NeOnc Technologies files to sell 680,558 shares of common stock for holders

2026-04-10T21:20:42.000Z - 2 months ago

NeOnc Technologies files to sell 680,558 shares of common stock for holders

NeOnc Technologies files $300M mixed securities shelf

2026-04-02T17:07:18.000Z - 2 months ago

NeOnc Technologies files $300M mixed securities shelf

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 9:00 AM EDT - 2 months ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies appoints Choi as Chief Accounting Officer

2026-03-13T13:05:36.000Z - 3 months ago

NeOnc Technologies appoints Choi as Chief Accounting Officer

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 3 months ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Mar 12, 2026, 8:52 AM EDT - 3 months ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

2026-03-04T13:06:31.000Z - 3 months ago

NeOnc Technologies reports Phase 1 dose-escalation results for NEO212

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Mar 4, 2026, 8:00 AM EST - 3 months ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Feb 27, 2026, 9:00 AM EST - 4 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

NeOnc Technologies files to sell 2.95M shares of common stock for holders

2026-02-06T21:55:14.000Z - 4 months ago

NeOnc Technologies files to sell 2.95M shares of common stock for holders

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

2026-01-30T14:17:11.000Z - 5 months ago

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 30, 2026, 9:00 AM EST - 5 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Jan 9, 2026, 7:32 PM EST - 5 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies announces updated NEO100 clinical results

2025-12-15T14:16:09.000Z - 6 months ago

NeOnc Technologies announces updated NEO100 clinical results

NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 6 months ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies files to sell 111.7K shares of common stock for holders

2025-12-15T13:00:48.000Z - 6 months ago

NeOnc Technologies files to sell 111.7K shares of common stock for holders

NeOnc Technologies announces preclinical findings from USC collaboration

2025-12-01T14:10:42.000Z - 7 months ago

NeOnc Technologies announces preclinical findings from USC collaboration

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 7 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

2025-11-13T14:16:23.000Z - 7 months ago

NeOnc Technologies completes full patient enrollment in NEO100-1 Phase 2a trial

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 7 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc announces updated results Phase 1/2a, compassionate care studies

2025-11-12T13:26:29.000Z - 7 months ago

NeOnc announces updated results Phase 1/2a, compassionate care studies

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 8 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

2025-11-04T14:05:59.000Z - 8 months ago

NeOnc Technologies appoints Heshmatpour as Chief Executive Officer

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

2025-10-28T13:10:14.000Z - 8 months ago

NeOnc says Sheikh Nahyan bin Zayed Al Nahyan assumes NuroMENA chairmanship

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

2025-10-09T13:10:30.000Z - 9 months ago

NeOnc Technologies’ NuroMENA signs master services agreement with M42’s IROS

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

2025-10-06T13:10:28.000Z - 9 months ago

NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 10 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 11 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 11 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 1 year ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 1 year ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 1 year ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 2 years ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 2 years ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 2 years ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

focafoca99
focafoca99 Jun. 22 at 2:11 PM
$NTHI benefited from Abu Dhabi IND authorization for NEO212, giving the biotech another development path.
0 · Reply
newsfile_corp
newsfile_corp Jun. 22 at 12:45 PM
https://nfne.ws/302323 $NTHI @wstprnews #BBIO #BIIB #BMY #LLY #NTHI #Advertising #Publishing #NASDAQ #Investing
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 22 at 8:58 AM
$NTHI A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE IND approval for NEO212. #NeOnc #NTHI #BrainCancer #Biotech #ClinicalTrials #UAE #AbuDhabi
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 18 at 6:17 AM
$NTHI NeOnc Technologies is proud to announce that we’ve secured UAE IND approval for NEO212 following successful Phase 1 completion, advancing toward global Phase 2 development. • Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol temozolomide conjugate, in the United Arab Emirates • Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose • Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-secures-uae-ind-approval-neo212-following
0 · Reply
focafoca99
focafoca99 Jun. 17 at 2:41 PM
$NTHI got IND approval in Abu Dhabi for its oral brain‑tumor therapy NEO212.
0 · Reply
BioRich
BioRich Jun. 17 at 11:32 AM
$XBI Nice article on some emerging opportunities from a breadth of sectors. Worth a read and look. My favorite is $SABS but haven't really had much exposure to the others. Anyone have a pros/cons on the others? $CUPR $HYFT $NTHI RGNT GELS? Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge https://stocktwits.com/news-articles///null/cZKfn9YbbdUg3
1 · Reply
STACKD0E
STACKD0E Jun. 17 at 2:00 AM
$MCRP $CRE $NTHI
0 · Reply
focafoca99
focafoca99 Jun. 16 at 6:19 PM
$NTHI snags Abu Dhabi IND approval for NEO212, giving the brain-cancer drug an international development path.
0 · Reply
focafoca99
focafoca99 Jun. 16 at 5:21 PM
$NTHI progressed with its first international IND clearance for NEO212 in the UAE, paving the way for Phase 2 development.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 2:03 PM
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development $NTHI https://stocktwits.com/news/others/business/ne-onc-technologies-secures-uae-ind-approval-for-neo-212-following-successful-phase-1-completion-advancing-toward-global-phase-2-development/cZKWr01R74c
0 · Reply
focafoca99
focafoca99 Jun. 15 at 12:47 PM
$NTHI bagged up to $5 million in financing via a securities purchase agreement for Series A Convertible Preferred Stock.
0 · Reply
newsfile_corp
newsfile_corp Jun. 15 at 12:37 PM
https://nfne.ws/301455 $NTHI @wstprnews #BAC #BCS #NTHI #Phase2 #STT #Advertising #Publishing #NASDAQ #Investing
0 · Reply
WHALECHASING
WHALECHASING Jun. 12 at 10:32 AM
$NTHI Why are you number one on the list? I don't see no action over here I don't see shit going on.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 11 at 8:48 AM
$NTHI ICYMI: In a recent interview with Lou Basenese, NeOnc Technologies CEO Amir Heshmatpour discussed the company’s innovative intranasal drug delivery platform designed to bypass the blood-brain barrier and deliver therapies directly to the brain. The conversation covers encouraging clinical data, including tumor remission observations, survival outcomes, upcoming Phase 2A milestones, pediatric compassionate use cases, and the broader potential of NeOnc’s platform across CNS diseases. Watch the full interview to learn more about NeOnc’s mission to advance treatment options for patients facing some of the most challenging forms of brain cancer. #NeOnc #NTHI #BrainCancer #Biotech #Oncology #ClinicalTrials #HealthcareInnovation https://www.youtube.com/watch?v=pUksENi0_78&t=1s
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 10 at 3:22 PM
$NTHI Watch: NeOnc Technologies reported first-quarter 2026 financial results while highlighting progress across its clinical-stage programs targeting central nervous system cancers. The company successfully completed the Phase 1 dose escalation study for NEO-212, establishing a recommended Phase 2 dose and advancing development toward key regulatory milestones. Management also reported encouraging early signs of clinical activity and potential durable disease stabilization in patients with recurrent glioblastoma multiforme (GBM) and brain metastases, despite the trial primarily being designed to evaluate safety. https://www.youtube.com/watch?v=VbMt9znHoXE
0 · Reply
newsfile_corp
newsfile_corp Jun. 9 at 12:46 PM
https://nfne.ws/300674 $NTHI @wstprnews #bloodbrainbarrier #CNS #GBM #NTHI #Oncology #Advertising #Publishing #NASDAQ #Investing
0 · Reply
Adriana88
Adriana88 Jun. 5 at 12:19 AM
$NTHI 6-7$ price target
1 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 4 at 10:09 AM
$NTHI Institutional awareness of NeOnc Technologies ($NTHI) continued to grow in May with two independent analyst firms initiating coverage: 🔹 Maxim Group: Buy Rating | $20 Price Target 🔹 BTIG: Buy Rating | $15 Price Target Both firms highlighted the potential of NeOnc's blood-brain-barrier bypassing platform and the advancement of its lead programs, NEO100 and NEO212. As we continue executing on our clinical and regulatory objectives, we appreciate the growing recognition of our mission to develop innovative therapies for patients with CNS cancers. Learn more about our latest announcements and Investor Relations updates at investors.neonc.com. #NTHI #NeOnc #Biotech #BrainCancer #Glioblastoma
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jun. 3 at 8:09 AM
$NTHI May demonstrated continued progress across multiple areas of the business, including clinical development, regulatory preparation, financial management, and growing awareness within the investment community. Highlights included: 🔹 Reported encouraging NEO100 tumor remission data, with 24% of recurrent glioblastoma patients achieving tumor remission 🔹 Announced Q1 2026 results and continued progress across both NEO100 and NEO212 programs 🔹 Received Buy ratings and price targets from both Maxim Group ($20 PT) and BTIG ($15 PT) 🔹 Advanced the fully enrolled NEO100 Phase 2a study and completed Phase 1 dose escalation for NEO212 🔹 CEO Amir Heshmatpour continued increasing his personal ownership through open-market stock purchases As we move through 2026, we remain focused on execution and advancing our clinical pipeline. We invite you to explore the latest company news, announcements, and insights in our Investor Relations section: https://investors.neonc.com/?_gl=1*hi4oxp*_ga*MzY3OTk0NjM2LjE3NzkwMTI1OTk.*_ga_VVQFTPL5V6*czE3ODAzMTQyNzckbzIkZzEkdDE3ODAzMTQ2MjYkajYwJGwwJGgw
0 · Reply
urban979
urban979 May. 31 at 9:23 PM
$NTHI Multiple Phase 2-stage programs: Phase IIa work underway for NEO100. Phase I/II development for NEO212.
1 · Reply
urban979
urban979 May. 31 at 9:16 PM
$NTHI Focused on high-need brain cancer markets. NeOnc is developing: NEO100 for recurrent high-grade gliomas and glioblastoma…
0 · Reply
NeOnc_Technologies
NeOnc_Technologies May. 24 at 8:34 AM
$NTHI We invite shareholders to take a closer look at one of the key financial takeaways from NeOnc’s Q1 2026 update: Approximately 31% of the company’s Q1 2026 net loss was related to non-cash stock-based compensation, resulting in normalized cash operating expenses of approximately $6.1 million for the quarter (~$24.4 million annualized). At the same time, NeOnc continued advancing both lead CNS oncology programs, including: • NEO212 advancing toward potential registrational Phase 2 discussions with the FDA • NEO100 Phase 2a remaining fully enrolled with interim data anticipated later this year The company remains focused on balancing clinical execution with operational discipline as multiple potential catalysts approach in 2026. Full update: https://investors.neonc.com/news-releases/news-release-details/neonc-provides-business-update-and-reports-q1-2026-financial
0 · Reply